PPIL GOES TO BIFR; NOVARTIS TO TAKE 2 WANDER PRODUCTS
Article Abstract:
Pharmaceutical Products of India Limited (PPIL) has been referred to the Board for Industrial and Financial Reconstruction (BIFR). It incurred losses of Rs48 crore on a turnover of Rs50 crore in 1997-98. The pharmaceutical firm Novartis (India) Ltd (NIL) plans to acquire two products, a cough and cold preparation, Triaminic and a nutritional product, Spert from Wander Ltd. Triaminic was licenced by Wander to PPIL three years ago. Wander is the subsidiary of PPIL. Novartis Nutrition India Private Limited, the group's nutrition company will acquire Spert in November 1998. Spert recorded sales of Rs5.27 crore while Triaminic recorded sales of Rs15 crore in 1997-98. NIL has targeted Rs20 crore from sales of Triaminic brand in 1998-99. (gsh)
Comment:
Plans to acquire two products, a cough & cold preparation, Triaminic & a nutritional product, Spert from Wander
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
A PLACE IN THE SUN
Article Abstract:
Sun Pharmaceuticals posted a net profit of Rs26.27 crore for the half year ended September 1998 (Rs26.16 crore for the half year ended September 1997). It had a compounded annual growth rate of 52 percent. Its income from exports grew by 94 percent. It has acquired several facilities in India and overseas to strengthen its presence in the domestic and international markets. Its total fixed assets has increased to Rs127 crore in March 1998 (Rs19 crore in March 1994). It has acquired stake in MJ Pharma, Gujarat Lyka and Caraco Pharmaceuticals of US. It has acquired the Ahmed Nagar plant of Knoll Pharmaceuticals. It has invested in research and development in the anti-cancer segment. (nr)
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
DEE-PHARMA SEEKS BIFR APPROVAL TO SELL PLANT
Article Abstract:
Dee-Pharma of Delhi has sought permission from the Board for Industrial and Financial Reconstruction (BIFR) to dispose off its bulk drugs unit at Bhiwadi in Rajasthan. The company plans to sell the unit for Rs7 crore and has also identified a buyer. It has also sought permission to sell its gelatine capsule plant at Ghaziabad. DEE-Pharma was declared sick in September 1998 and had been directed not to dispose off any fixed or current assets without the consent of the BIFR. (khr)
Comment:
Dee-Pharma of Delhi has sought permission from the Board for Industrial and Financial Reconstruction (BIFR) to dispose off its bulk drugs unit at Bhiwadi in Rajasthan.
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: SHIPPING SECTOR IN ROUGH WATERS SHAHI SHIPPING'S NET DIPS BY 2.8% L&T TO SELL OFF SHIPPING DIVISION FOR $40 MILLION
- Abstracts: MAX GROUP MULLS WAYS TO DISTRIBUTE Rs563-CRORE GAIN DRS TO DISTRIBUTE WEBRAMP RANGE OF PRODUCTS. MARICO IND TO DISTRIBUTE TOP RAMEN FOR INDO-NISSIN
- Abstracts: SAIL TO GO EASY IN WEST, SOUTH INDIAN MARKETS ISPAT LOOKS TO GERMAN MAJORS FOR FINANCING NEW HR PLANT RINL PLANNING EXPORT OF FURNACE SLAG
- Abstracts: HLL ON DIRECT SELLING MODE. CREAMY CREAM. HLL INVESTING Rs 40 CR IN SILVASSA UNIT
- Abstracts: SUN TV TO CALL SECOND TELUGU CHANNEL `TEJA'. INDIA'S FIRST URDU CHANNEL GOES ON AIR. BUOYED BY NRS RESULTS, GEMINI PLANS SECOND TELUGU CHANNEL